Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avalon GloboCare ( (ALBT) ) has provided an announcement.
On February 19, 2026, Avalon GloboCare entered into a securities purchase agreement with an accredited investor, issuing a $233,910 promissory note with a 12% one-time interest charge for $207,000 in gross proceeds, with staged repayments running from August 15, 2026 through February 15, 2027. The unregistered note includes default conversion features into common stock at a discount to market, asset-disposition restrictions, and ownership and share-issuance caps that both provide financing flexibility and limit immediate dilution for existing shareholders.
On February 24, 2026, three directors, William B. Stilley, III, Wilbert J. Tauzin II and Tevi Troy, resigned from Avalon GloboCare’s board and all committees, with the company stating their departures did not stem from disagreements over operations or governance. The board moved the same day to refill these roles, naming Lourdes Felix and Michael Mathews to key committee posts and appointing Steven Sanders as lead independent director and compensation chair, signaling an effort to maintain board continuity and oversight amid the new financing structure.
More about Avalon GloboCare
Avalon GloboCare Corp. operates in the healthcare and life sciences sector, focusing on developing and commercializing medical and biotechnology solutions. The company accesses capital markets through structured securities and note financings to support its operations and strategic initiatives, while maintaining governance structures that rely on an active, independent board and specialized committees.
Average Trading Volume: 279,619
Technical Sentiment Signal: Sell
Current Market Cap: $2.28M
Learn more about ALBT stock on TipRanks’ Stock Analysis page.